- Home
- KALV
as 02-21-2025 4:00pm EST
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 362.2M | IPO Year: | N/A |
| Target Price: | $25.67 | AVG Volume (30 days): | 321.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.30 - $15.50 | Next Earning Date: | 03-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 17 '25 | Sell | $9.82 | 5,104 | $50,142.72 | 278,855 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 17 '25 | Sell | $9.82 | 2,601 | $25,552.74 | 92,745 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 17 '25 | Sell | $9.82 | 3,125 | $30,700.62 | 100,334 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 12 '25 | Buy | $9.28 | 161,700 | $1,498,661.00 | 5,278,985 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Jan 30 '25 | Buy | $8.96 | 70,023 | $621,628.02 | 5,278,985 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Dec 6 '24 | Sell | $9.75 | 7,627 | $74,363.25 | 278,855 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
Business Wire
21 hours ago
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
Business Wire
12 days ago
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
Business Wire
18 days ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
KalVista Says Japan Health Ministry Grants Orphan Drug Designation to Sebetralstat
Business Wire
a month ago
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
Business Wire
a month ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT Newswires
2 months ago
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.